Scholarlink

<p>There is limited data on the risk of stroke in patients with acute myocardial infarction (AMI) treated with temporary mechanical circulatory support devices. Retrospective data were extracted from the U.S. National Inpatient Sample between October 2015 and December 2020, involving hospitalizations for AMI<i>.</i> The final cohort comprised: 4,370,069 hospitalizations with medical therapy only, 136,005 with intra-aortic balloon pump (IABP) only, 41,560 with Impella only, and 10,695 with extracorporeal membrane oxygenation (ECMO) utilized during hospitalization. The overall stroke rates for patients receiving medical therapy only, IABP only, Impella only, and ECMO were 3.39%, 3.56%, 4.54%, and 13.14%, respectively. Specifically, ischemic stroke rates were 2.93%, 3.17%, 3.96%, and 9.91%, and hemorrhagic stroke rates were 0.69%, 0.59%, 0.87%, and 4.77% for the respective groups. In stepwise forward Cox regression analysis, ECMO use was associated with the highest adjusted odds ratio (aOR) for overall stroke (aOR 3.04, 95% CI [2.66–3.48]), followed by Impella alone (aOR 1.79, 95% CI [1.61–2.00]) and atrial fibrillation (aOR 1.34, 95% CI [1.31–1.38]). However, IABP use showed no significant association with increased stroke risk in either univariate or multivariate analyses. While IABP use is not associated with an increased risk of ischemic or hemorrhagic stroke, ECMO and Impella use are linked to a higher stroke risk, particularly for ECMO-treated AMI.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

ECMO and impella increase stroke risk in acute myocardial infarction

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月14日

查看全文
  • Jing Wu,
  • Chenguang Li,
  • Zheng Xu,
  • Baoguo Wang,
  • Mingyou Zhang

摘要

There is limited data on the risk of stroke in patients with acute myocardial infarction (AMI) treated with temporary mechanical circulatory support devices. Retrospective data were extracted from the U.S. National Inpatient Sample between October 2015 and December 2020, involving hospitalizations for AMI. The final cohort comprised: 4,370,069 hospitalizations with medical therapy only, 136,005 with intra-aortic balloon pump (IABP) only, 41,560 with Impella only, and 10,695 with extracorporeal membrane oxygenation (ECMO) utilized during hospitalization. The overall stroke rates for patients receiving medical therapy only, IABP only, Impella only, and ECMO were 3.39%, 3.56%, 4.54%, and 13.14%, respectively. Specifically, ischemic stroke rates were 2.93%, 3.17%, 3.96%, and 9.91%, and hemorrhagic stroke rates were 0.69%, 0.59%, 0.87%, and 4.77% for the respective groups. In stepwise forward Cox regression analysis, ECMO use was associated with the highest adjusted odds ratio (aOR) for overall stroke (aOR 3.04, 95% CI [2.66–3.48]), followed by Impella alone (aOR 1.79, 95% CI [1.61–2.00]) and atrial fibrillation (aOR 1.34, 95% CI [1.31–1.38]). However, IABP use showed no significant association with increased stroke risk in either univariate or multivariate analyses. While IABP use is not associated with an increased risk of ischemic or hemorrhagic stroke, ECMO and Impella use are linked to a higher stroke risk, particularly for ECMO-treated AMI.